82 reports

Mice models for anxiety disorders have been useful for providing information on brain and behavioral mechanisms involved in the etiology and physiopathology of anxiety disorders.

  • Oncology
  • North America
  • United States
  • World
  • Horizon Discovery

One of the most common anxiety disorders for people with alopecia is obsessive compulsive disorder (Ghanizadeh and Ayoobzadehshirazi, 2014; Schu, 2015).

  • Oncology
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.

The patent covers methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided.

  • Oncology
  • Personality Disorder
  • Therapy
  • United States
  • Product Initiative

It also conducts clinical and preclinical development of drug candidates for indications such as addiction, Charcot-Marie-Tooth Type ##a (CMT##A) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder, autism and other disorders, Parkinson' s disease,

  • Cancer
  • Oncology
  • United States
  • Product Initiative
  • Exelixis, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • NEURODEGENERATIVE DISEASE, GLOBAL, LICENSING DEALS WITH DISCLOSED DEAL VALUES,

Caregivers of AD patients may also display symptoms of depression and anxiety when caring for loved ones with the disease.

  • Oncology
  • Therapy
  • Company
  • Company Financials
  • Forecast
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Monoclonal Antibody
  • Oncology
  • Pharmaceutical
  • Therapy
  • GlaxoSmithKline plc

The prominent features of this report are - ##.

  • Clinical Trial
  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 44 Trial Title
  • Target

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Teva Pharmaceutical Industries Ltd.

Presented data from the IMPACT study at the World Congress of Psychiatric Genetics demonstrating that GeneSight statistically significantly improved anxiety symptom severity in ## patients with generalized anxiety disorder.

  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • United States
  • Grifols, S.A.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Genetic Disorder
  • Oncology
  • CSL Limited

The prominent features of this report are - ##.

  • Drug Development
  • Oncology
  • Pharmaceutical
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Drug Development
  • Medical Biotechnology
  • Oncology
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • World

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Chronic Disease
  • Clinical Trial
  • Oncology
  • World

## ## ## ## China ## ## ## ## ## ## ## Brazil ## ## ## ## ## ## ## Mexico ## ## ## ## ## ## ## Turkey ## ## ## ## ## ## ## Russia ## ## ## ## ## ## ## Indonesia Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database

  • Clinical Trial
  • Oncology
  • Type 2 Diabetes
  • World
  • Product Initiative
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

## ## ## ## Aeterna Zentaris Inc ## ## ## ## Pfizer Inc ## ## ## ## Novartis AG ## ## ## ## Celgene Corp ## ## ## ## C.

  • Oncology
  • Therapy
  • World
  • Product Initiative
  • Burzynski Research Institute, Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Chemotherapy
  • Clinical Trial
  • Oncology
  • Therapy
  • World

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## ## ## Eisai Co Ltd ## ##

  • Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • Oncology
  • Therapy
  • Pfizer Inc.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • Oncology
  • Novartis AG

The prominent features of this report are - ##.

  • Chemotherapy
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • NEUROPATHIC PAIN - PIPELINE BY BIOGEN INC, H1 2018
  • NEUROPATHIC PAIN - PIPELINE BY BCN PEPTIDES SA, H1 2018

IT WAS ALSO UNDER DEVELOPMENT FOR THE TREATMENT OF ANXIETY DISORDERS.

  • Chronic Pain
  • Oncology
  • Pharmaceutical
  • Therapy
  • Can-Fite BioPharma Ltd.

The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, mens health and musculoskeletal problems.

  • Oncology
  • Therapy
  • United States
  • World
  • Product Initiative

The Company intends to use the proceeds to complete its ongoing Phase II/ III clinical trial of trigriluzole for the treatment of SCA. anxiety disorders such as obsessive-compulsive disorder, are provided.

  • Immunotherapy
  • Lymphoma
  • Oncology
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Monoclonal Antibody
  • Oncology
  • Pharmaceutical
  • World
  • Product Initiative

Hoffmann-La Roche Ltd ## ## ## ## ## ## C.

  • Brain Cancer
  • Oncology
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

In the study, ## patients were randomized ##:##:## to receive placebo, baricitinib ## mg or baricitinib ## mg.

  • Medical Biotechnology
  • Musculoskeletal Disorder
  • Oncology
  • World
  • GlaxoSmithKline plc